The Use of Immunoglobulin Therapy for Patients Undergoing Solid Organ Transplantation: An Evidence-Based Practice Guideline

Nadine Shehata; Valerie A. Palda; Ralph M. Meyer; Tom D. Blydt-Hansen; Patricia Campbell; Carl Cardella; Steven Martin; Peter Nickerson; Kevork Peltekian; Heather Ross; Tom K. Waddell; Lori West; David Anderson; John Freedman; Heather Hume

doi:10.1016/j.tmrv.2009.09.010

The Use of Immunoglobulin Therapy for Patients Undergoing Solid Organ Transplantation: An Evidence-Based Practice Guideline

Nadine Shehata, Valerie A. Palda, Ralph M. Meyer, Tom D. Blydt-Hansen, Patricia Campbell, Carl Cardella, Steven Martin, Peter Nickerson, Kevork Peltekian, Heather Ross, Tom K. Waddell, Lori West, David Anderson, John Freedman, Heather Hume

Medicine

Research output: Contribution to journal › Article › peer-review

90 Citations (Scopus)

Abstract

This guideline for the use of immunoglobulin (IG) for sensitized patients undergoing solid organ transplantation (SOT) is an initiative of the Canadian Blood Services and the National Advisory Committee on Blood and Blood Products of Canada to (1) provide guidance for Canadian practitioners involved in the care of patients undergoing SOT and transfusion medicine specialists on the use of IG and (2) standardize care, limit adverse events, and optimize patient care. A systematic expert and bibliography literature search up to July 2008 was conducted, with 791 literature citations and 45 reports reviewed. To validate the recommendations, the guideline was sent to physicians involved in SOT in Canada and a patient representative. The recommendations identify (1) sensitized patients undergoing SOT that would have a better survival and decreased morbidity by receiving IG preoperatively, postoperatively, and for the treatment of organ rejection; (2) patients who may not have any benefit from receiving IG; and (3) potential adversities to IG.

Original language	English
Pages (from-to)	S7-S27
Journal	Transfusion Medicine Reviews
Volume	24
Issue number	SUPPL. 1
DOIs	https://doi.org/10.1016/j.tmrv.2009.09.010
Publication status	Published - Jan 2010

Bibliographical note

Funding Information:
STATEMENT OF CONFLICT OF INTEREST: Dr L West receives research funding from the US National Institutes of Health (Grant P01-HL079067). Drs Nadine Shehata and Peter Nickerson are employees of Canadian Blood Services, as were Drs Heather Hume and John Freedman during the period of the development of these guidelines. Funding was provided from an unrestricted education grant from Bayer, Inc, to Canadian Blood Services. Bayer did not have any role in the selection of panel members, the literature search, the selection of articles, or the development of the recommendations.

ASJC Scopus Subject Areas

Hematology
Clinical Biochemistry
Biochemistry, medical

Access to Document

10.1016/j.tmrv.2009.09.010

Cite this

Shehata, N., Palda, V. A., Meyer, R. M., Blydt-Hansen, T. D., Campbell, P., Cardella, C., Martin, S., Nickerson, P., Peltekian, K., Ross, H., Waddell, T. K., West, L., Anderson, D., Freedman, J., & Hume, H. (2010). The Use of Immunoglobulin Therapy for Patients Undergoing Solid Organ Transplantation: An Evidence-Based Practice Guideline. Transfusion Medicine Reviews, 24(SUPPL. 1), S7-S27. https://doi.org/10.1016/j.tmrv.2009.09.010

Shehata, N, Palda, VA, Meyer, RM, Blydt-Hansen, TD, Campbell, P, Cardella, C, Martin, S, Nickerson, P, Peltekian, K, Ross, H, Waddell, TK, West, L, Anderson, D, Freedman, J & Hume, H 2010, 'The Use of Immunoglobulin Therapy for Patients Undergoing Solid Organ Transplantation: An Evidence-Based Practice Guideline', Transfusion Medicine Reviews, vol. 24, no. SUPPL. 1, pp. S7-S27. https://doi.org/10.1016/j.tmrv.2009.09.010

@article{ba2aca5858ac4227b73df3433d88d913,

title = "The Use of Immunoglobulin Therapy for Patients Undergoing Solid Organ Transplantation: An Evidence-Based Practice Guideline",

abstract = "This guideline for the use of immunoglobulin (IG) for sensitized patients undergoing solid organ transplantation (SOT) is an initiative of the Canadian Blood Services and the National Advisory Committee on Blood and Blood Products of Canada to (1) provide guidance for Canadian practitioners involved in the care of patients undergoing SOT and transfusion medicine specialists on the use of IG and (2) standardize care, limit adverse events, and optimize patient care. A systematic expert and bibliography literature search up to July 2008 was conducted, with 791 literature citations and 45 reports reviewed. To validate the recommendations, the guideline was sent to physicians involved in SOT in Canada and a patient representative. The recommendations identify (1) sensitized patients undergoing SOT that would have a better survival and decreased morbidity by receiving IG preoperatively, postoperatively, and for the treatment of organ rejection; (2) patients who may not have any benefit from receiving IG; and (3) potential adversities to IG.",

author = "Nadine Shehata and Palda, {Valerie A.} and Meyer, {Ralph M.} and Blydt-Hansen, {Tom D.} and Patricia Campbell and Carl Cardella and Steven Martin and Peter Nickerson and Kevork Peltekian and Heather Ross and Waddell, {Tom K.} and Lori West and David Anderson and John Freedman and Heather Hume",

note = "Funding Information: STATEMENT OF CONFLICT OF INTEREST: Dr L West receives research funding from the US National Institutes of Health (Grant P01-HL079067). Drs Nadine Shehata and Peter Nickerson are employees of Canadian Blood Services, as were Drs Heather Hume and John Freedman during the period of the development of these guidelines. Funding was provided from an unrestricted education grant from Bayer, Inc, to Canadian Blood Services. Bayer did not have any role in the selection of panel members, the literature search, the selection of articles, or the development of the recommendations. ",

year = "2010",

month = jan,

doi = "10.1016/j.tmrv.2009.09.010",

language = "English",

volume = "24",

pages = "S7--S27",

journal = "Transfusion Medicine Reviews",

issn = "0887-7963",

publisher = "W.B. Saunders Ltd",

number = "SUPPL. 1",

}

TY - JOUR

T1 - The Use of Immunoglobulin Therapy for Patients Undergoing Solid Organ Transplantation

T2 - An Evidence-Based Practice Guideline

AU - Shehata, Nadine

AU - Palda, Valerie A.

AU - Meyer, Ralph M.

AU - Blydt-Hansen, Tom D.

AU - Campbell, Patricia

AU - Cardella, Carl

AU - Martin, Steven

AU - Nickerson, Peter

AU - Peltekian, Kevork

AU - Ross, Heather

AU - Waddell, Tom K.

AU - West, Lori

AU - Anderson, David

AU - Freedman, John

AU - Hume, Heather

N1 - Funding Information: STATEMENT OF CONFLICT OF INTEREST: Dr L West receives research funding from the US National Institutes of Health (Grant P01-HL079067). Drs Nadine Shehata and Peter Nickerson are employees of Canadian Blood Services, as were Drs Heather Hume and John Freedman during the period of the development of these guidelines. Funding was provided from an unrestricted education grant from Bayer, Inc, to Canadian Blood Services. Bayer did not have any role in the selection of panel members, the literature search, the selection of articles, or the development of the recommendations.

PY - 2010/1

Y1 - 2010/1

N2 - This guideline for the use of immunoglobulin (IG) for sensitized patients undergoing solid organ transplantation (SOT) is an initiative of the Canadian Blood Services and the National Advisory Committee on Blood and Blood Products of Canada to (1) provide guidance for Canadian practitioners involved in the care of patients undergoing SOT and transfusion medicine specialists on the use of IG and (2) standardize care, limit adverse events, and optimize patient care. A systematic expert and bibliography literature search up to July 2008 was conducted, with 791 literature citations and 45 reports reviewed. To validate the recommendations, the guideline was sent to physicians involved in SOT in Canada and a patient representative. The recommendations identify (1) sensitized patients undergoing SOT that would have a better survival and decreased morbidity by receiving IG preoperatively, postoperatively, and for the treatment of organ rejection; (2) patients who may not have any benefit from receiving IG; and (3) potential adversities to IG.

AB - This guideline for the use of immunoglobulin (IG) for sensitized patients undergoing solid organ transplantation (SOT) is an initiative of the Canadian Blood Services and the National Advisory Committee on Blood and Blood Products of Canada to (1) provide guidance for Canadian practitioners involved in the care of patients undergoing SOT and transfusion medicine specialists on the use of IG and (2) standardize care, limit adverse events, and optimize patient care. A systematic expert and bibliography literature search up to July 2008 was conducted, with 791 literature citations and 45 reports reviewed. To validate the recommendations, the guideline was sent to physicians involved in SOT in Canada and a patient representative. The recommendations identify (1) sensitized patients undergoing SOT that would have a better survival and decreased morbidity by receiving IG preoperatively, postoperatively, and for the treatment of organ rejection; (2) patients who may not have any benefit from receiving IG; and (3) potential adversities to IG.

UR - http://www.scopus.com/inward/record.url?scp=71249110321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71249110321&partnerID=8YFLogxK

U2 - 10.1016/j.tmrv.2009.09.010

DO - 10.1016/j.tmrv.2009.09.010

M3 - Article

C2 - 19962580

AN - SCOPUS:71249110321

SN - 0887-7963

VL - 24

SP - S7-S27

JO - Transfusion Medicine Reviews

JF - Transfusion Medicine Reviews

IS - SUPPL. 1

ER -

The Use of Immunoglobulin Therapy for Patients Undergoing Solid Organ Transplantation: An Evidence-Based Practice Guideline

Abstract

Bibliographical note

ASJC Scopus Subject Areas

Access to Document

Other files and links

Fingerprint

Cite this